Lexicon Pharmaceuticals (LXRX) Competitors

$2.01 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.98 -0.03 (-1.54%)

As of 06/18/2026 07:43 PM Eastern

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? MarketBeat compares Lexicon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.93	-$50.34M	-$0.07	N/A
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Celldex Therapeutics	N/A	-50.72%	-46.59%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Celldex Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Celldex Therapeutics and 0 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.38 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Celldex Therapeutics	Neutral

Lexicon Pharmaceuticals presently has a consensus target price of $4.55, suggesting a potential upside of 126.37%. Celldex Therapeutics has a consensus target price of $49.30, suggesting a potential upside of 52.02%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, suggesting a potential upside of 126.37%. BioCryst Pharmaceuticals has a consensus target price of $20.70, suggesting a potential upside of 130.26%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

BioCryst Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.93	-$50.34M	-$0.07	N/A
BioCryst Pharmaceuticals	$874.84M	2.61	$263.86M	-$1.78	N/A

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 1 mentions for BioCryst Pharmaceuticals and 0 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.67 beat BioCryst Pharmaceuticals' score of 0.27 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
BioCryst Pharmaceuticals	Neutral

Lexicon Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Lexicon Pharmaceuticals' return on equity of -18.64% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

BioCryst Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Innoviva had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 1 mentions for Innoviva and 0 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.67 beat Innoviva's score of 0.34 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Innoviva	Neutral
Lexicon Pharmaceuticals	Positive

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74
Lexicon Pharmaceuticals	$49.80M	17.93	-$50.34M	-$0.07	N/A

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 60.96%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 126.37%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Innoviva has a net margin of 119.89% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Innoviva's return on equity of 33.33% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Summary

Innoviva beats Lexicon Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Novavax?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Lexicon Pharmaceuticals presently has a consensus target price of $4.55, indicating a potential upside of 126.37%. Novavax has a consensus target price of $13.00, indicating a potential upside of 42.39%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has a net margin of -14.73% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Novavax's return on equity of -14.82% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Novavax had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Novavax and 0 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.67 beat Novavax's score of 0.11 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Novavax	Neutral

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.93	-$50.34M	-$0.07	N/A
Novavax	$1.12B	1.34	$440.30M	-$0.58	N/A

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Novavax beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Zenas BioPharma had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Zenas BioPharma and 0 mentions for Lexicon Pharmaceuticals. Zenas BioPharma's average media sentiment score of 1.33 beat Lexicon Pharmaceuticals' score of 0.67 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Zenas BioPharma	Positive
Lexicon Pharmaceuticals	Positive

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zenas BioPharma presently has a consensus price target of $44.29, indicating a potential upside of 123.89%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 126.37%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Lexicon Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
Lexicon Pharmaceuticals	$49.80M	17.93	-$50.34M	-$0.07	N/A

Summary

Lexicon Pharmaceuticals beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$892.84M	$3.39B	$6.42B	$12.60B
Dividend Yield	N/A	2.31%	2.68%	5.68%
P/E Ratio	-28.71	19.56	24.49	24.43
Price / Sales	17.93	323.62	530.07	109.30
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	6.70	8.16	10.83	6.58
Net Income	-$50.34M	$23.89M	$3.57B	$337.17M
7 Day Performance	4.69%	2.55%	0.77%	0.82%
1 Month Performance	-9.05%	2.33%	1.41%	3.25%
1 Year Performance	168.00%	55.03%	29.35%	36.02%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.6609 of 5 stars	$2.01 flat	$4.55 +126.4%	+169.6%	$892.84M	$49.80M	N/A	140
CLDX Celldex Therapeutics	2.1739 of 5 stars	$32.12 +2.7%	$49.30 +53.5%	+55.8%	$2.45B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	2.6231 of 5 stars	$9.06 +4.1%	$20.70 +128.5%	-9.7%	$2.21B	$874.84M	N/A	530
INVA Innoviva	3.8403 of 5 stars	$22.42 -1.4%	$36.20 +61.5%	+4.8%	$1.68B	$411.33M	3.73	100	News Coverage Gap Up
NVAX Novavax	1.7823 of 5 stars	$9.21 +3.7%	$12.13 +31.7%	+44.9%	$1.46B	$1.12B	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 6/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Which has preferable valuation & earnings, LXRX or CLDX?

Is LXRX or CLDX more profitable?

Do institutionals & insiders hold more shares of LXRX or CLDX?

Which has more risk & volatility, LXRX or CLDX?

Does the media refer more to LXRX or CLDX?

Do analysts prefer LXRX or CLDX?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Do analysts prefer LXRX or BCRX?

Which has preferable earnings and valuation, LXRX or BCRX?

Does the media favor LXRX or BCRX?

Which has more volatility and risk, LXRX or BCRX?

Do institutionals & insiders have more ownership in LXRX or BCRX?

Is LXRX or BCRX more profitable?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Does the media refer more to INVA or LXRX?

Do insiders & institutionals hold more shares of INVA or LXRX?

Which has higher earnings & valuation, INVA or LXRX?

Which has more risk & volatility, INVA or LXRX?

Do analysts rate INVA or LXRX?

Is INVA or LXRX more profitable?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Do analysts rate LXRX or NVAX?

Is LXRX or NVAX more profitable?

Does the media favor LXRX or NVAX?

Which has more volatility & risk, LXRX or NVAX?

Which has better earnings and valuation, LXRX or NVAX?

Do institutionals and insiders believe in LXRX or NVAX?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Does the media refer more to ZBIO or LXRX?

Do insiders and institutionals believe in ZBIO or LXRX?

Do analysts prefer ZBIO or LXRX?

Which has more volatility and risk, ZBIO or LXRX?

Is ZBIO or LXRX more profitable?

Which has better earnings & valuation, ZBIO or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools